| 注册
首页|期刊导航|中国医药科学|不同剂量卵清蛋白诱导支气管哮喘小鼠模型探讨

不同剂量卵清蛋白诱导支气管哮喘小鼠模型探讨

陈琼华 林春燕 张俊垚 郑敬阳 程晶 黄小艺

中国医药科学2025,Vol.15Issue(9):19-22,64,5.
中国医药科学2025,Vol.15Issue(9):19-22,64,5.DOI:10.20116/j.issn2095-0616.2025.09.04

不同剂量卵清蛋白诱导支气管哮喘小鼠模型探讨

Investigation of mice model of bronchial asthma induced by different doses of ovalbumin

陈琼华 1林春燕 1张俊垚 1郑敬阳 1程晶 2黄小艺3

作者信息

  • 1. 福建省泉州市妇幼保健院·儿童医院呼吸科,福建 泉州 362000
  • 2. 泉州市医学高等专科学校动物实验中心,福建 泉州 362000
  • 3. 泉州市医学高等专科学校药学院,福建 泉州 362000
  • 折叠

摘要

Abstract

Objective To investigate the methods of creating a mouse model of bronchial asthma and the optimal sensitization dose of ovalbumin(OVA).Methods Thirty BALB/c mice were randomly divided into the control group,the model group 1(OVA 10 μg,sensitization 2 times),the model group 2(OVA 20 μg,sensitization 2 times),the model group 3(OVA 20 μg,sensitization 3 times),and the model group 4(OVA 50 μg,sensitization 3 times).The serum levels of interleukin(IL)-4,IL-5,IL-13,interferon(IFN)-γ and IgE in mice were detected to evaluate the pathological changes in lung tissue.Results Compared with the control group,the levels of IL-4,IL-5,IL-13,and IgE in the serum of the model groups 1,2,3 and 4 were significantly increased,while the levels of IFN-γ were significantly decreased(P<0.05).Inflammatory cell infiltration was observed in the lung pathology,and the tracheal wall was significantly thickened,and the lumen was narrowed.In them,the model group 1 showed the most significant changes in IL-4 and IL-13,and the model group 3 showed the most significant changes in IFN-γ and IgE.The pathological changes in lung tissue were most pronounced in the model group 3.Conclusion 4 doses of OVA sensitization can establish mice model of bronchial asthma.OVA 20 μg/time and sensitization 3 times may be the most suitable dose for modeling in this experiment.

关键词

支气管哮喘/卵清蛋白/剂量/BALB/c小鼠

Key words

Bronchial asthma/Ovalbumin/Dose/BALB/c mice

分类

基础医学

引用本文复制引用

陈琼华,林春燕,张俊垚,郑敬阳,程晶,黄小艺..不同剂量卵清蛋白诱导支气管哮喘小鼠模型探讨[J].中国医药科学,2025,15(9):19-22,64,5.

基金项目

华侨大学院校联合创新项目(2022YX001). (2022YX001)

中国医药科学

2095-0616

访问量0
|
下载量0
段落导航相关论文